Nova Mentis to Present Promising Psilocybin Microdose Data at 18th NFXF International Fragile X Conference
Nova Mentis to Present Promising Psilocybin Microdose Data at 18th NFXF International Fragile X Conference
Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it will be discussing the therapeutic potential of oral microdose psilocybin for the treatment of autism spectrum disorder (ASD) and fragile X syndrome (FXS) during a poster presentation at the 18th NFXF International Fragile X Conference, taking place July 14-17, 2022 in San Diego, California.
温哥華，不列顛哥倫比亞省-(Newsfile Corp.-2022年7月11日)-Nova Mentis生命科學公司(CSE：NOVA)(FSE：HN3Q)(OTCQB：NMLSF)(“Nova”或“公司”)，一家生物技術公司和一流的以裸蓋菇素為基礎的療法和神經炎性疾病輔助診斷領域的全球領先企業很高興地宣佈，它將在2022年7月14-17日在加利福尼亞州聖地亞哥舉行的第18屆NFXF國際脆性X大會的海報演示中討論口服微劑量裸蓋菇素治療自閉症譜系障礙(ASD)和脆性X綜合徵(FXS)的潛力。
Dr. Marvin S. Hausman, the Chairman of NOVA's Scientific Advisory Board, will deliver a presentation titled: A Novel Psilocybin Microdose Treatment of Fragile X Syndrome. NOVA's recent research results showed that a very low microdose formulation of the Company's proprietary psilocybin drug (NM-1001) significantly modulated behavioural and cognitive defects, in a genetic model of FXS.
Nova科學諮詢委員會主席Marvin S.Hausman博士將發表題為：一種新的裸蓋菇素治療脆性X綜合徵。Nova公司最近的研究結果表明，該公司的裸蓋菇素專利藥物(NM-1001)的極低劑量配方顯著調節了FXS遺傳模型中的行為和認知缺陷。
Poster Presentation Details:
海報演示文稿詳情：
| Presentation Title: | A Novel Psilocybin Microdose Treatment of Fragile X Syndrome |
| Date: | Friday, July 15, 2022 |
| Poster Reception Time: | 4:30 pm - 6:30 pm |
| 演示文稿標題： | 一種新的裸蓋菇素治療脆性X綜合徵 |
| 日期： | 2022年7月15日(星期五) |
| 海報接收時間： | 下午4：30至6：30 |
A video of NOVA's presentation will be made available on the NFXF event app during the conference and the Company's website following the event.
Nova演講的視頻將在會議期間在NFXF活動應用程序上提供，並在活動結束後在公司網站上提供。
About Nova Mentis Life Science Corp.
關於Nova Mentis生命科學公司
Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of Fragile X Syndrome (FXS).
Nova Mentis生命科學公司是一家總部位於加拿大的生物技術公司，在開發神經炎性疾病的診斷和基於裸蓋菇素的療法方面處於全球領先地位。Nova是第一家在美國和歐盟獲得使用裸蓋菇素治療脆性X綜合徵(FXS)的孤兒藥物指定的生物技術公司。
Our goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS.
我們的目標是診斷和治療那些沒有滿足醫療需求的令人衰弱的慢性疾病，如自閉症譜系障礙(ASD)和FXS。
For further information on the Company, please visit or email info@novamentis.ca.
欲瞭解更多有關公司的信息，請訪問或發送電子郵件至info@novamentis.ca。
On Behalf of the Board
我謹代表董事會
Will Rascan, President & CEO
Nova Mentis Life Science Corp.
威爾·拉斯坎，總裁兼首席執行官
Nova Mentis生命科學公司
Phone: 778-819-0244
Toll Free: 1-833-542-5323
電話：778-819-0244
免費電話：1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc
推特：@novamentislsc
Instagram：@novamentislsc
臉書：@novamentislsc
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
加拿大證券交易所及其市場監管機構(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
本新聞稿包含構成“前瞻性陳述”的陳述。此類前瞻性表述涉及已知和未知的風險、不確定性和其他因素，可能導致Nova Mentis生命科學公司的實際結果、業績或成就或行業發展與此類前瞻性表述明示或暗示的預期結果、業績或成就大不相同。前瞻性陳述是指不是歷史事實的陳述，通常但並非總是由“預期”、“計劃”、“預期”、“相信”、“打算”、“估計”、“項目”、“潛在”和類似的表述，或事件或條件“將”、“將”、“可能”、“可能”或“應該”發生。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。